This clinical trial is focused on studying a condition known as ischemic stroke, which occurs when a blood clot blocks or narrows an artery leading to the brain, causing a reduction in blood flow. The study is specifically looking at patients with a large area of brain damage, referred to as a large ischemic core, who are eligible for a procedure called endovascular therapy (EVT). This therapy involves using a catheter to remove the clot and restore blood flow. The trial will test a treatment called Glenzocimab, which is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. Glenzocimab is being compared to a placebo to see if it can improve the chances of a good recovery three months after the stroke.

In addition to Glenzocimab, the study involves the use of GADOVIST, a contrast agent used in imaging tests to help visualize blood vessels and tissues more clearly. This agent is administered through an intravenous injection. The trial will also use a 0.9% sodium chloride solution, which is a common fluid used in medical settings. The main goal of the study is to determine if Glenzocimab can help patients achieve better functional outcomes, which means being able to perform daily activities more independently, three months after their stroke.

Participants in the study will receive either Glenzocimab or a placebo, and their progress will be monitored over a period of three months. The study will assess various outcomes, including the presence of any bleeding in the brain, the overall recovery of brain function, and the rate of survival. The trial aims to provide valuable information on whether Glenzocimab can be an effective treatment option for patients with ischemic stroke and a large ischemic core, potentially improving their quality of life after the stroke.